Christopher Lawson Bowlus, M.D.
Chief, Division of Gastroenterology and Hepatology
Lena Valente Professor
To see if Christopher Lawson Bowlus is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Midtown Ambulatory Care Center
Midtown GI Clinic
3160 Folsom Blvd
Sacramento, CA 95816
Phone: 916-734-0779
UC Davis Medical Group - Davis (West Covell Boulevard)
UC Davis Medical Group - Davis (West Covell Boulevard)
2440 West Covell Blvd
Davis, CA 95616
Additional Numbers
Clinic Phone
Clinic Fax
Physician Referrals
Philosophy of Care
Technology has led to tremendous improvements in the care of patients, but the physician's greatest tool remains the ability to listen.
Clinical Interests
Dr. Christopher L. Bowlus specializes in care of patients with liver disease and has expertise in the management of autoimmune liver diseases, specifically primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis.
Research/Academic Interests
Dr. Bowlus is interested in elucidating the underlying genetic and immunologic causes of autoimmune liver diseases and using this information to develop more effective treatments for these conditions.
Division
Gastroenterology and Hepatology
Center/Program Affiliation
Undergraduate School
B.A., Biochemistry, UC San Diego, San Diego CA 1985
Medical School
M.D., St. Louis University School of Medicine, St. Louis MO 1990
Internship
Internal Medicine, UC Davis Medical Center, Sacramento CA 1990-1993
Residency
Internal Medicine, UC Davis Medical Center, Sacramento CA 1990-1993
Fellowship
Gastroenterology, Yale University School of Medicine, New Haven CT 1993-1996
Internal Medicine Faculty Research Award, 2020
PSC Partners Seeking a Cure Golden Liver Award, 2016
PSC Partners Seeking a Cure Visionary Award, 2014
Walter Trudeau Excellence in Teaching Award, 2013
PSC Partners Seeking a Cure Partner of the Year, 2011
Link to SciVal profile: https://ucdavis.pure.elsevier.com/en/persons/christopher-bowlus
Ponsioen CY, Assis DN, Boberg KM, Bowlus CL, Deneau M, Thorburn D, Aabakken L, Färkkilä M, Petersen B, Rupp C, Hübscher SG; PSC Study Group. Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology. 2021 Dec;161(6):1764-1775.e5. doi:10.1053/j.gastro.2021.07.046. Epub 2021 Aug 10. PMID:34384749.
Li J, Lu M, Zhou Y, Bowlus CL, Lindor K, Rodriguez-Watson C, Romanelli RJ, Haller IV, Anderson H, VanWormer JJ, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Wu KH, Trudeau S, Rupp LB, Melkonian C, Gordon SC; FOLD Investigators. Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. Dig Dis Sci. 2021 Sep 9. doi:10.1007/s10620-021-07219-4. Epub ahead of print. PMID:34499271.
Maverakis E, Merleev AA, Park D, Kailemia MJ, Xu G, Ruhaak LR, Kim K, Hong Q, Li Q, Leung P, Liakos W, Wan YY, Bowlus CL, Marusina AI, Lal NN, Xie Y, Luxardi G, Lebrilla CB. Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. Clin Immunol. 2021 Sep;230:108825. doi: 10.1016/j.clim.2021.108825. Epub 2021 Aug 14. PMID: 34403816.
Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C. Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clin Gastroenterol Hepatol. 2021 Aug 30:S1542-3565(21)00919-8. doi:10.1016/j.cgh.2021.08.039. Epub ahead of print. PMID:34474162.
Mazi TA, Borkowski K, Newman JW, Fiehn O, Bowlus CL, Sarkar S, Matsukuma K, Ali MR, Kieffer DA, Wan YY, Stanhope KL, Havel PJ, Medici V. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med. 2021 Aug 20;172:490-502. doi:10.1016/j.freeradbiomed.2021.06.024. Epub 2021 Jun 25. PMID:34182070.
Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin AN, Myers RP, Goodman Z, Landi A, Houghton M, Green RM, Levy C, Kowdley KV, Bowlus CL, Muir AJ, Trauner M. A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. Hepatology. 2021 Mar;73(3):1105-1116. doi:10.1002/hep.31488. Epub 2021 Feb 28. PMID:32745270.